These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
156 related articles for article (PubMed ID: 16283256)
1. Population pharmacokinetic analysis of drug-drug interactions among risperidone, bupropion, and sertraline in CF1 mice. Wang JS; DeVane CL; Gibson BB; Donovan JL; Markowitz JS; Zhu HJ Psychopharmacology (Berl); 2006 Jan; 183(4):490-9. PubMed ID: 16283256 [TBL] [Abstract][Full Text] [Related]
2. P-glycoprotein interaction with risperidone and 9-OH-risperidone studied in vitro, in knock-out mice and in drug-drug interaction experiments. Ejsing TB; Pedersen AD; Linnet K Hum Psychopharmacol; 2005 Oct; 20(7):493-500. PubMed ID: 16118767 [TBL] [Abstract][Full Text] [Related]
3. Carbamazepine-risperidone interactions in patients with epilepsy. Mula M; Monaco F Clin Neuropharmacol; 2002; 25(2):97-100. PubMed ID: 11981236 [TBL] [Abstract][Full Text] [Related]
4. An in vitro mechanistic study to elucidate the desipramine/bupropion clinical drug-drug interaction. Reese MJ; Wurm RM; Muir KT; Generaux GT; St John-Williams L; McConn DJ Drug Metab Dispos; 2008 Jul; 36(7):1198-201. PubMed ID: 18420781 [TBL] [Abstract][Full Text] [Related]
5. The brain entry of risperidone and 9-hydroxyrisperidone is greatly limited by P-glycoprotein. Wang JS; Ruan Y; Taylor RM; Donovan JL; Markowitz JS; DeVane CL Int J Neuropsychopharmacol; 2004 Dec; 7(4):415-9. PubMed ID: 15683552 [TBL] [Abstract][Full Text] [Related]
6. Effects of sertraline on the pharmacokinetics of bupropion and its major metabolite, hydroxybupropion, in mice. Molnari JC; Hassan HE; Myers AL Eur J Drug Metab Pharmacokinet; 2012 Mar; 37(1):57-63. PubMed ID: 21928040 [TBL] [Abstract][Full Text] [Related]
7. Plasma pharmacokinetic characteristics of risperidone and their relationship to saliva concentrations in children with psychiatric or neurodevelopmental disorders. Aman MG; Vinks AA; Remmerie B; Mannaert E; Ramadan Y; Masty J; Lindsay RL; Malone K Clin Ther; 2007 Jul; 29(7):1476-86. PubMed ID: 17825699 [TBL] [Abstract][Full Text] [Related]
8. Bupropion for major depressive disorder: Pharmacokinetic and formulation considerations. Jefferson JW; Pradko JF; Muir KT Clin Ther; 2005 Nov; 27(11):1685-95. PubMed ID: 16368442 [TBL] [Abstract][Full Text] [Related]
9. Rifampin, a cytochrome P450 3A inducer, decreases plasma concentrations of antipsychotic risperidone in healthy volunteers. Mahatthanatrakul W; Nontaput T; Ridtitid W; Wongnawa M; Sunbhanich M J Clin Pharm Ther; 2007 Apr; 32(2):161-7. PubMed ID: 17381666 [TBL] [Abstract][Full Text] [Related]
10. A study of genetic (CYP2D6 and ABCB1) and environmental (drug inhibitors and inducers) variables that may influence plasma risperidone levels. Leon Jd; Susce MT; Pan RM; Wedlund PJ; Orrego ML; Diaz FJ Pharmacopsychiatry; 2007 May; 40(3):93-102. PubMed ID: 17541883 [TBL] [Abstract][Full Text] [Related]
11. In vitro and in vivo evaluation of the inhibition potential of risperidone toward clozapine biotransformation. Chetty M; d'Esposito F; Zhang WV; Glen J; Dore G; Stankovic Z; Edwards RJ; Ramzan I; Murray M Br J Clin Pharmacol; 2009 Oct; 68(4):574-9. PubMed ID: 19843060 [TBL] [Abstract][Full Text] [Related]
12. CYP2B6 mediates the in vitro hydroxylation of bupropion: potential drug interactions with other antidepressants. Hesse LM; Venkatakrishnan K; Court MH; von Moltke LL; Duan SX; Shader RI; Greenblatt DJ Drug Metab Dispos; 2000 Oct; 28(10):1176-83. PubMed ID: 10997936 [TBL] [Abstract][Full Text] [Related]
13. Effect of verapamil on pharmacokinetics and pharmacodynamics of risperidone: in vivo evidence of involvement of P-glycoprotein in risperidone disposition. Nakagami T; Yasui-Furukori N; Saito M; Tateishi T; Kaneo S Clin Pharmacol Ther; 2005 Jul; 78(1):43-51. PubMed ID: 16003291 [TBL] [Abstract][Full Text] [Related]
14. Mechanism of an unusual, but clinically significant, digoxin-bupropion drug interaction. He J; Yu Y; Prasad B; Chen X; Unadkat JD Biopharm Drug Dispos; 2014 Jul; 35(5):253-63. PubMed ID: 24436229 [TBL] [Abstract][Full Text] [Related]
16. Dose-related effects of clozapine and risperidone on the pattern of brain regional serotonin and dopamine metabolism and on tests related to extrapyramidal functions in rats. Batool F; Hasnat A; Haleem MA; Haleem DJ Acta Pharm; 2010 Jun; 60(2):129-40. PubMed ID: 21134850 [TBL] [Abstract][Full Text] [Related]
17. Brain, plasma and tissue pharmacokinetics of risperidone and 9-hydroxyrisperidone after separate oral administration to rats. Aravagiri M; Marder SR Psychopharmacology (Berl); 2002 Feb; 159(4):424-31. PubMed ID: 11823895 [TBL] [Abstract][Full Text] [Related]
18. Blonanserin, a novel atypical antipsychotic agent not actively transported as substrate by P-glycoprotein. Inoue T; Osada K; Tagawa M; Ogawa Y; Haga T; Sogame Y; Hashizume T; Watanabe T; Taguchi A; Katsumata T; Yabuki M; Yamaguchi N Prog Neuropsychopharmacol Biol Psychiatry; 2012 Oct; 39(1):156-62. PubMed ID: 22691713 [TBL] [Abstract][Full Text] [Related]
19. Transport of Bupropion and its Metabolites by the Model CHO and HEK293 Cell Lines. Han LW; Gao C; Zhang Y; Wang J; Mao Q Drug Metab Lett; 2019; 13(1):25-36. PubMed ID: 30488806 [TBL] [Abstract][Full Text] [Related]
20. The buccal mucosa as an alternative route for the systemic delivery of risperidone. Heemstra LB; Finnin BC; Nicolazzo JA J Pharm Sci; 2010 Nov; 99(11):4584-92. PubMed ID: 20845457 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]